title: Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours.
abstract: BACKGROUND
  Stroke outcomes are worse in patients admitted at nonworking hours (NWH), but whether this is also true in patients treated with intravenous (i.v.) thrombolysis has not been definitely proven.
  
  
  OBJECTIVE
  Our aim was to test the hypothesis that stroke patients treated by i.v. rt-PA at NWH have a worse outcome than those treated at working hours (WH).
  
  
  METHODS
  We compared outcomes at 7 days and at 3 months, between patients treated at NWH and at WH in the stroke unit of the Lille University Hospital.
  
  
  RESULTS
  Of 252 consecutive patients [median age: 69 years; 132 men (52.4%); median National Institutes of Health Stroke Scale score: 14; median onset-to-needle time: 150 min], 134 (53.2%) were treated at NWH. They did not differ for baseline characteristics and proportion of patients with modified Rankin Scale scores 0-1 and 0-2 at 3 months. Patients treated at WH were more likely to die before 7 days (12.7 vs. 4.5%; adjusted odds ratio: 3.6; 95% confidence interval: 1.2-10.4) and at 3 months (21.6 vs. 11.4%; adjusted odds ratio: 2.2; 95% confidence interval: 1.02-4.7). The causes of death did not differ between NWH and WH. At NWH, there was no difference in baseline characteristics and outcomes of patients treated by stroke- and nonstroke neurologists.
  
  
  CONCLUSIONS
  The case fatality rates were unexpectedly higher at WH than at NWH. If this finding can be reproduced and is not a chance finding, we should identify explanations, especially organisational issues, chronobiological factors or summation of subtle--nonsignificant--baseline differences.
authors.affiliation: Department of Neurology, University Hospital of Lille, Lille, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Bodenant
authors.forename: Didier
authors.initials: D
authors.lastname: Leys
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Debette
authors.forename: Charlotte
authors.initials: C
authors.lastname: Cordonnier
authors.forename: Frédéric
authors.initials: F
authors.lastname: Dumont
authors.forename: Hilde
authors.initials: H
authors.lastname: Hénon
authors.forename: Marie
authors.initials: M
authors.lastname: Girot
authors.forename: Christian
authors.initials: C
authors.lastname: Lucas
authors.forename: David
authors.initials: D
authors.lastname: Devos
authors.forename: Luc
authors.initials: L
authors.lastname: Defebvre
authors.forename: Dominique
authors.initials: D
authors.lastname: Deplanque
authors.forename: Xavier
authors.initials: X
authors.lastname: Leclerc
authors.forename: Régis
authors.initials: R
authors.lastname: Bordet
mesh_terms: D000208:Acute Disease; D039602:After-Hours Care; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016009:Chi-Square Distribution; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005602:France; D006801:Humans; D007262:Infusions, Intravenous; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010043:Outcome and Process Assessment, Health Care; D010561:Personnel Staffing and Scheduling; D011994:Recombinant Proteins / Q000008:administration & dosage; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000401:mortality; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator